Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

ClinicalTrials.gov ID: NCT03517449

Public ClinicalTrials.gov record NCT03517449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer

Study identification

NCT ID
NCT03517449
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eisai Inc.
Industry
Enrollment
827 participants

Conditions and interventions

Interventions

  • Pembrolizumab Drug
  • Lenvatinib Drug
  • Paclitaxel Drug
  • Doxorubicin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 10, 2018
Primary completion
Feb 28, 2022
Completion
Feb 25, 2025
Last update posted
Mar 18, 2026

2018 – 2025

United States locations

U.S. sites
25
U.S. states
17
U.S. cities
25
Facility City State ZIP Site status
Arizona Oncology Associates, PC- HAL Phoenix Arizona 85016
University of California San Francisco San Francisco California 94158
University of California Los Angeles Santa Monica California 90095
Smilow Cancer Hospital at Yale New Haven New Haven Connecticut 06510
University of Miami Health System Miami Florida 33136
Florida Hospital Cancer Institute Orlando Florida 32804
Georgia Cancer Center at Augusta University Augusta Georgia 30912
North Shore University Health System Evanston Illinois 60201
University Medical Center New Orleans New Orleans Louisiana 70112
Greater Baltimore Medical Center Baltimore Maryland 21204
Maryland Oncology Hematology, P.A. Wheaton Maryland 20902
John Theurer Cancer Center at Hackensack University Med Ctr Hackensack New Jersey 07601
Holy Name Medical Center Teaneck New Jersey 07666
Memorial Sloan Kettering Cancer Center New York New York 10022
University of Rochester Rochester New York 14642
Duke University Medical Center Durham North Carolina 27710
Stephenson Cancer Center Oklahoma City Oklahoma 73104
Willamette Valley Cancer Institute and Research Center Eugene Oregon 97401
Sanford Gynecology Oncology Sioux Falls South Dakota 57104
UT West Cancer Center Germantown Tennessee 38138
Texas Oncology-South Austin Austin Texas 78745
University of Texas Southwestern Medical Center at Dallas Dallas Texas 75390-9032
The University of Texas MD Anderson Cancer Center Houston Texas 77030
Texas Oncology-San Antonio Medical Center San Antonio Texas 78240
Utah Cancer Specialists Salt Lake City Utah 84106

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 144 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03517449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 18, 2026 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03517449 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →